Table 1.
Patient and Disease Characteristics at Time of TNF Inhibitor Initiation in Patients Who Continued Their Initial Treatment for ≥6 Months
| Characteristic | Patients using initial TNF inhibitor for ≥6 months (N = 1732) |
|---|---|
| Female, N (%) | 1294 (74.7) |
| White, N (%) | 1502 (86.7) |
| Age, median (IQR) | 56 (16.0) |
| BMI, median (IQR) | 28.2 (8.6) |
| Duration of RA, median, yrs (IQR) | 3 (8) |
| CDAI score, median (IQR) | 23.8 (16) |
| Moderate disease activity,a N (%) | 777 (44.9) |
| High disease activity,b N (%) | 955 (55.1) |
| Tender joints, median (IQR) | 8 (8) |
| Swollen joints, median (IQR) | 7 (8) |
| mHAQ-DI, median (IQR) | .5 (.8) |
| Patient pain, median rating (IQR) | 50 (45) |
| Patient global assessment, median rating (IQR) | 50 (44) |
| Patient-reported fatigue, median rating (IQR) | 50 (55) |
| Morning stiffness, median, hrs (IQR) | 1 (1.8) |
| Prednisone use, N (%) | 612 (35.3) |
| Previous csDMARDs (including current), median, N (IQR) | 1 (1) |
| TNF inhibitor monotherapy, N (%) | 230 (13.3) |
| TNF inhibitor combination therapy, N (%) | 1502 (86.7) |
| Methotrexate alone | 984 (56.8) |
| Other csDMARD | 235 (13.6) |
| Methotrexate plus other csDMARD | 283 (16.3) |
| Initial TNF inhibitor, N (%) | |
| Adalimumab | 558 (32.2) |
| Etanercept | 541 (31.2) |
| Infliximab | 506 (29.2) |
| Certolizumab pegol | 87 (5.0) |
| Golimumab | 40 (2.3) |
a
CDAI score 10–22.
b
CDAI score >22.
BMI indicates body mass index; CDAI, Clinical Disease Activity Index; csDMARD, conventional synthetic disease-modifying antirheumatic drug; IQR, interquartile range; mHAQ-DI, modified Health Assessment Questionnaire-Disability Index; RA, rheumatoid arthritis; TNF, tumor necrosis factor.